Frequently asked questions
The global multiple sclerosis treatment market was valued at USD 24.9 Billion in 2022.
The multiple sclerosis treatment market is expected to grow at a CAGR of 4.1% between 2023 and 2030, reaching USD 32.9 Billion in 2030.
Interferons is the leading segment by Route of administration, holding over 30% share in value in 2022.
The Injectables segment governs the global demand for multiple sclerosis treatment, holding a massive share of over 35% in 2022.
The hospital pharmacy equipment segment is expected to post the highest CAGR during the forecast period.
North America is fueling the growth of the multiple sclerosis treatment industry, with an over one-third share in 2022.
The top players include Pfizer, Bayer AG, Teva Pharmaceutical Industries Ltd, Novartis AG, Sanofi, and F. Hoffmann-La Roche Ltd.
The major market drivers are the increasing prevalence of multiple sclerosis, advancements in therapeutic options, and a growing focus on personalized medicine and precision therapies.
The major market restraints are the high cost of multiple sclerosis treatments and adverse side effects associated with some therapies.
Development of novel therapies, personalized and precision therapies, expansion into emerging markets, and technological advancements in diagnostics and monitoring tools.